FDA Clears AI-Powered Stroke Imaging Tool for Non-Contrast CT
Through artificial intelligence (AI) assessment of non-contrast computed tomography (CT) scans, the Brainomix 360 e-ASPECTS software provides an automated ASPECTS score and heatmap to enhance stroke imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Brainomix 360 e-ASPECTS software (Brainomix), which provides adjunctive artificial intelligence (AI) assessment of computed tomography (CT) scans of the brain and automated scoring with the Alberta Stroke Program Early CT score (ASPECTS) system.
As part of the Brainomix 360 stroke platform, which emphasizes real-time AI-enabled interpretation of brain imaging in stroke patients, the e-ASPECTS software provides enhanced heatmap visualization and automated ASPECTS scoring based on non-contrast CT scans, according to Brainomix.
The company said recent studies have demonstrated the stroke imaging platform’s ability to reduce door-in door-out times and reportedly triple the number of patients regaining functional independence after stroke.
“Our e-ASPECTS tool has been shown, in multiple countries and healthcare systems, to improve physicians’ interpretations of ASPECTS scores on non-contrast CT scans … ,” noted Michalis Papadakis, CEO and co-founder of Brainomix. “Our technology supports these physicians who are making time-sensitive, critical decisions around transfer and treatment, strengthening networks and facilitating an improved stroke service.”
(Editor’s note: For related content, see “Portable MRI System Gets FDA Nod for AI-Powered Brain Imaging Software” and “TeraRecon Launches AI-Driven Neuroimaging Platform.”)
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
